CCR8 and neoplasm: In contrast, when tumor bearing mice were treated with 225Ac-anti-CCR8 mAb - there was statistically significant slowing down of CT26 and MC38 tumor growth with 14.8 kBq 225Ac-anti-CCR8 mAb and with 7.4 kBq 225Ac-anti-CCR8 mAb - of CT26 tumors.